Tenon Medical, Inc. — Q3 2023 Form 10-Q Summary
Business Context and Reporting Period
Tenon Medical is a medical-device company commercializing the FDA-cleared Catamaran SI Joint Fusion System, a titanium implant system for sacroiliac-joint disorders. The company launched nationally in October 2022 and is focused primarily on the U.S. market. This unaudited Form 10-Q covers the three and nine months ended September 30, 2023, compared with the corresponding 2022 periods.
Financial Performance and Liquidity
| Metric | Q3 2023 | Q3 2022 | 9M 2023 | 9M 2022 |
|---|---|---|---|---|
| Revenue | $0.944 million | $0.208 million | $2.120 million | $0.414 million |
| Gross profit (loss) | $0.535 million | $(0.094) million | $0.682 million | $(0.434) million |
| Gross margin | 57% | (45%) | 32% | (105%) |
| Operating loss | $(3.378) million | $(3.262) million | $(12.586) million | $(10.797) million |
| Net loss | $(3.332) million | $(3.171) million | $(12.447) million | $(11.012) million |
| Net loss per share | $(1.46) | $(2.82) | $(7.91) | $(15.91) |
| Cash used in operations | Not separately provided | Not separately provided | $(9.905) million | $(8.640) million |
- Revenue increased 354% in Q3 and 412% for the first nine months, primarily because the number of surgical procedures using the Catamaran System increased 329% and 404%, respectively.
- Operating expenses were $3.913 million in Q3 and $13.268 million for the first nine months. Sales and marketing increased substantially as the company expanded its sales organization, commissions, and transition activities.
- Cash and cash equivalents were $3.371 million at September 30, 2023; short-term investments were zero, compared with $6.441 million at year-end 2022. Total current assets were $4.963 million versus current liabilities of $3.085 million.
- The company had no outstanding debt at September 30, 2023. Total liabilities were $4.801 million, including $2.724 million of accrued commissions and $0.743 million of operating lease liabilities.
- Net cash provided by investing activities was $6.234 million, primarily from sales and maturities of short-term investments. Financing activities provided $4.931 million, including equity offerings and related proceeds.
- Accumulated deficit was $51.939 million, and stockholders’ equity was $2.517 million.
Material Changes Versus the Prior Comparable Period
- Commercial traction improved materially: nine-month revenue rose from $0.414 million to $2.120 million, and gross margin improved from negative 105% to positive 32%.
- Despite higher revenue, the nine-month net loss increased by $1.435 million, reflecting increased sales and marketing and research and development spending.
- Sales and marketing expense increased 90% for the first nine months, driven primarily by higher payroll, transition expenses, commissions, and stock-based compensation.
- Research and development expense increased 23% for the first nine months, while general and administrative expense decreased 2%.
- Operating cash burn increased 15% year over year to $9.905 million.
- The company raised approximately $4.808 million net in a June 2023 registered offering of 1,000,000 units and approximately $0.453 million net through its at-the-market program. The June offering included 2,000,000 warrants; the warrant exercise price subsequently reset from $5.60 to $3.146 per share.
- Shares outstanding increased to 2,471,014 at September 30, 2023 from 1,123,680 at December 31, 2022, before giving effect to the subsequent reverse stock split.
Guidance, Outlook, Risks, and Unusual Items
- No specific revenue, earnings, or cash-flow guidance was provided. Management expects operating expenses and losses to continue as commercialization, sales expansion, product development, and clinical activities proceed.
- Management stated that existing cash and cash equivalents would not fund operations and working-capital requirements for at least twelve months from issuance of the financial statements. The filing includes substantial doubt about the company’s ability to continue as a going concern.
- Management expects to seek additional funding through equity offerings, debt financing, and collaborations. Additional equity financing could dilute existing stockholders; debt financing could impose restrictive covenants. Failure to obtain financing could require reductions or delays in sales, research, development, or other activities.
- Nasdaq notified the company of deficiencies involving the $1.00 minimum bid-price requirement and the $2.5 million minimum stockholders’ equity requirement. Stockholders approved a reverse-split authorization, and the company effected a 1-for-10 reverse stock split on November 2, 2023.
- The company’s disclosure controls and procedures were determined to be ineffective because limited resources prevented adequate segregation of accounting duties, constituting a material weakness in internal control.
- The terminated sales representative agreement requires payments tied to product sales, with an estimated accrued commission liability of $2.535 million at September 30, 2023 and an expected aggregate expense of up to $3.600 million under the applicable provisions.
- Operating lease commitments totaled $0.830 million, including $0.075 million due within one year. The filing reports no material changes to previously disclosed risk factors and no material litigation proceedings.
- The filing contains an apparent inconsistency: the financial statements report total Q3 operating expenses of $3.913 million, while one MD&A comparison table presents $3.613 million. The financial-statement amount should be verified against the filed XBRL data.
Important Facts for Investors to Verify
- Verify the company’s near-term financing plans, cash runway, and ability to address the disclosed going-concern uncertainty.
- Assess whether procedure volume and revenue growth can continue while sales and marketing costs increase.
- Review the dilution and potential share issuance associated with the 2,000,000 warrants, the at-the-market program, and the Lincoln Park equity line of credit for up to $10 million.
- Confirm Nasdaq compliance following the November 2023 1-for-10 reverse stock split and monitor the minimum-equity requirement.
- Evaluate the material weakness in disclosure controls and management’s remediation progress.
- Reconcile the operating-expense discrepancy in MD&A and confirm all post-quarter-end share counts and per-share amounts after the reverse split.